Sclerotherapy for Simple Cysts with Use of Ethanolamine Oleate: Preliminary Experience

Yamamoto, K; Sakaguchi, Hiroshi; Anai, Hiroshi; Tanaka, Toshihiro; Morimoto, Kengo; Kichikawa, Kimihiko; Uchida, Hideo

doi:10.1007/s00270-004-0277-0

Cited by 36 publications

(45 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The emerging data (Table 3) [12,19,20,[23][24][25][26][27][28][29][30] suggest that sclerotherapy could be a viable alternative to open/laparoscopic deroofing of cysts. However, no randomized controlled trial comparing the two modalities exists to date, and the differing end-points reported by most studies make comparison of the two procedures difficult.…”

Section: Discussionmentioning

confidence: 96%

Nine-Year Single-Center Experience with Nonparastic Liver Cysts: Diagnosis and Management

et al. 2006

View full text Add to dashboard Cite

This study presents the experience with laparoscopic deroofing of nonparasitic liver cysts at a single center over a 9-year period. A total of 25 patients, undergoing 32 operations, were identified. Median cyst diameter was 10 cm for de novo cysts and 9.5 cm for recurrent cysts. Six patients had multiple cysts consistent with polycystic liver disease. In total, there were 26 laparoscopic procedures and 2 open conversions. Four procedures were commenced as open, three of which were for recurrent cysts. Minor complications were bleeding from a port site (n=1), pneumothorax (n=2), and intra-abdominal collection (n=1). One major complication of bile leak and relaparotomy occurred following an open deroofing. No major complications were recorded for laparoscopic procedures. Symptomatic recurrence of cysts occurred in four patients with simple cysts (5%) and one patient with polycystic liver disease. We conclude that laparoscopic liver cyst deroofing is an effective method of dealing with symptomatic nonparasitic liver cysts.

show abstract

Section: Discussionmentioning

confidence: 96%

Nine-Year Single-Center Experience with Nonparastic Liver Cysts: Diagnosis and Management

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Monoethanolamine oleate (EO) sclerotherapy therapy was performed and reported by Yamamoto et al [11] in a small number of patients. We also performed the procedure for 17 cysts in 13 patients and previously reported a volume reduction rate of 93.3% and a recurrence rate of 0% [12].…”

Section: Introductionmentioning

confidence: 99%

Monoethanolamine Oleate Sclerotherapy for Polycystic Liver Disease

Takita¹,

Iwanishi²,

Minami³

et al. 2016

Dig Dis

View full text Add to dashboard Cite

Objective: The objective of treatment for polycystic liver disease is to reduce the liver volume and reduce or resolve compression symptoms such as abdominal fullness and abdominal pain due to hepatomegaly. Liver cysts are treated internally by puncture and aspiration of the cyst contents or hepatic artery embolization and surgically by cyst fenestration or hepatectomy, but no clear consensus has been reached concerning their selection. We introduced monoethanolamine oleate (EO) sclerotherapy therapy for liver cysts in 1999 and reported its effectiveness. In this study, cases were added, and the results including those of long-term follow-up were evaluated. Subjects: Twenty-two patients (5 males and 17 females, mean age 65.2) who underwent EO infusion therapy for liver cysts between January 1999 and June 2011 were evaluated. Methods: Liver cysts were punctured under ultrasound guidance, and a 7Fr pigtail catheter was inserted. After aspirating the cyst contents, EO was infused, and a clamp was applied for 24 h. Then, the catheter was declamped, cyst contents were aspirated again, and the catheter was removed. After the treatment, the cyst size was measured, and the patients were followed up. Results: Eight simple cysts in 8 patients (simple cyst group) and 21 cysts in 14 patients with multiple cysts (polycystic liver disease group) were treated and followed up over a median of 78 months (0-203 months). The mean volume reduction rate was 99% in the simple cyst group and 91% in the polycystic liver disease group (p = 0.04). One procedural accident resulting in liver abscess formation was observed in 1 patient 1 week after discharge, and it required drain placement and antibiotic administration. While mild abdominal pain was observed in a few patients, it was resolved spontaneously under observation. Conclusion: EO infusion therapy achieves fairly high treatment response in the volume reduction (99%) and sustained shrinkage over long-term follow-up. Therefore, this is a breakthrough technique in the treatment of polycystic liver disease as well as simple cyst and should be a standard of care in the treatment of this disease.

show abstract

“…This agent can also be administered extravascularly into cystic structures, thereby inducing an inflammatory response on the luminal surface of the cysts, resulting in the adhesion of the cyst walls [24]. This agent has been used successfully in adult medicine in the management of hydroceles [25] and in the sclerosis of various cystic structures [24,26]. …”

Section: Discussionmentioning

confidence: 99%

Treatment of Congenital Pulmonary Airway Malformation Induced Hydrops Fetalis via Percutaneous Sclerotherapy

et al. 2012

View full text Add to dashboard Cite

Large type II and III congenital pulmonary airway malformations (CPAMs) can cause pulmonary hypoplasia, non-immune hydrops fetalis and fetal demise. Fetal intervention is indicated if hydrops fetalis develops. In this report, we describe three cases of type II and III CPAMs complicated by hydrops and treated with percutaneous sclerotherapy by ethanolamine injection into the tumor. All 3 cases demonstrated reduction in size of the CPAM and resolution of the hydrops with subsequent delivery at term. We believe that fetal percutaneous sclerotherapy can be used as a minimally invasive palliative strategy to treat CPAM-induced hydrops fetalis. Further studies are needed to delineate the risks of this novel technique.

show abstract

Sclerotherapy for Simple Cysts with Use of Ethanolamine Oleate: Preliminary Experience

Cited by 36 publications

References 6 publications

Nine-Year Single-Center Experience with Nonparastic Liver Cysts: Diagnosis and Management

Nine-Year Single-Center Experience with Nonparastic Liver Cysts: Diagnosis and Management

Monoethanolamine Oleate Sclerotherapy for Polycystic Liver Disease

Treatment of Congenital Pulmonary Airway Malformation Induced Hydrops Fetalis via Percutaneous Sclerotherapy

Contact Info

Product

Resources

About